ABSTRACT
Background and aims Functional dyspepsia is characterised by chronic symptoms of post- prandial distress or epigastric pain not associated with defined structural pathology. Increased peripheral gut-homing T cell have been previously identified in patients. To date, it is unknown if these T cells were antigen-experienced, or if a specific immunophenotype was associated with FD. This study aimed to characterise immune populations in the blood and duodenal mucosa of FD patients that may be implicated in disease pathophysiology.
Methods We identified duodenal T cell populations from 23 controls and 49 Rome III FD patients by flow cytometry. We also analysed duodenal eosinophils and T cell populations in peripheral blood from 37 controls and 49 patients and investigated if subtyping patients based on reported symptoms or co-morbidity identified specific immunophenoptypes.
Results In addition to increased duodenal mucosal CD4+ effector cells, FD patients demonstrated a shift in the T helper cell balance compared to controls. Patients had increased duodenal mucosal Th2 populations in the effector (13.03±16.11, 19.84±15.51, p=0.038), central memory (23.75±18.97, 37.52±17.51, p=0.007) and effector memory (9.80±10.50 vs 20.53±14.15, p=0.001) populations. Th17 populations were also increased in the effector (31.74±24.73 vs 45.57±23.75, p=0.03) and effector memory (11.95±8.42 vs 18.44±15.63, p=0.027) subsets.
Conclusion Our findings confirm the involvement of adaptive responses in the aetiopathogenesis of FD, specifically a Th2 and Th17 signature in the duodenal mucosa. The presence of effector and memory cells suggest that the microinflammation in FD is antigen driven.
Competing Interest Statement
DISCLOSURES: GLB, JB, RC, MDEP, KM, AM, CN, PMN, PSF, JH: None to disclose GH: Unrestricted educational support from Bayer Ptd, Ltd and the Falk Foundation. Research support was provided via the Princess Alexandra Hospital, Brisbane by GI Therapies Pty Limited, Takeda Development Center Asia, Pty Ltd, Eli Lilly Australia Pty Limited, F.Hoffmann-La Roche Limited, MedImmune Ltd Celgene Pty Limited, Celgene International II Sarl, Gilead Sciences Pty Limited, Quintiles Pty Limited, Vital Food Processors Ltd, Datapharm Australia Pty Ltd Commonwealth Laboratories, Pty Limited, Prometheus Laboratories, Falk GmbH and Co Kg, Nestle Pty Ltd, Mylan. Patent Holder: A biopsy device to take aseptic biopsies (US 20150320407 A1) MV: Grant/Research Support: NIHR [IBD clinical], LIVErNORTH [Hepatology clinical] NP: Advisory board fees from Abbvie, Allergan, Debiopharm International, Ferring, and Vifor Pharma and lecture fees from Allergan and Falk Pharma. MMW: Grant/research support: Prometheus Laboratories Inc (Irritable bowel syndrome [IBS] Diagnostic), Commonwealth Diagnostics International (biomarkers for FGIDs). NJT: Grant/research support: Rome Foundation; Abbott Pharmaceuticals; Datapharm; Pfizer; Salix (irritable bowel syndrome); Prometheus Laboratories Inc (Irritable bowel syndrome [IBS] Diagnostic); Janssen (constipation). Consultant/Advisory Boards: Allakos (IBS), Adelphi Values (functional dyspepsia [patient reported outcome measures]; [Budesonide]); GI therapies (chronic constipation [Rhythm IC]); Allergens PLC; Napo Pharmaceutical; Outpost Medicine; Samsung Bioepis; Yuhan (IBS); Synergy (IBS); Theravance (gastroparesis). Patent holder: Biomarkers of irritable bowel syndrome; Licensing Questionnaires (Mayo Clinic Talley Bowel Disease Questionnaire Mayo Dysphagia Questionnaire); Nestec European Patent (Application No. 12735358.9); Singapore Provisional Patent (NTU Ref: TD/129/17 Microbiota Modulation of BDNF Tissue Repair Pathway). SK: Grant/research support: Cancer Institute NSW (Career Development Fellowship), National Health and Medical Research Council (Centre of Research Excellence, Project and Ideas Grant), Viscera Labs, Gossamer Bio, Anatara Lifesciences, Microba (Funded research and consultancy).
Funding Statement
This study was supported by a grant from the National Health and Medical Research Council (NHMRC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All research was undertaken in accordance with approvals from the Hunter New England (reference 13/12/11/3.01) and Metro South Health (reference HREC/13/QPAH/690) Human Research Ethics Committees
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
